CISCER (PAX1/JAM3) Methylation Testing: The 'Double-Insurance Scout' of Cervical Cancer Screening
Many women, when they hear "cervical cancer," feel it's far removed from them. Busy with work, burdened with household duties, feeling a bit "embarrassed" to get checked... many women keep postponing regular screening. But by the time the body sounds the alarm, the optimal treatment window has often passed — truly regrettable! In fact, cervical cancer in its early stages is like a "quietly lurking enemy" with virtually no symptoms, but regular screening is the "all-seeing eye" that can catch it — like the first ray of dawn before sunrise, uncovering lesions when they are still small and controllable, with cure rates reaching over 90%. Truly, "prevention is better than cure."
01 The "Pain Points" of Traditional Screening: Like Seeing Through Fog
Currently, high-risk human papillomavirus (hr-HPV) testing is the preferred method for cervical cancer screening, and cervical exfoliative cytology serves as a triage method for HPV-positive patients.
HPV testing checks for infection with high-risk human papillomavirus (the main "culprit" of cervical cancer). But it has a problem: it is extremely sensitive to the presence of high-risk viruses but cannot distinguish between "transient visitors" that will be cleared by the immune system and "lingering guests" that may progress to lesions. This leads to a relatively high false-positive rate, causing unnecessary worry. Many people can clear the virus on their own after infection (over 90%). So while HPV testing has high sensitivity, it struggles to distinguish "passersby" from "stayers." This easily causes "false alarms" and unnecessary worry.
Cervical smear/cytology (TCT/LCT): Physicians examine cervical cells under a microscope for lesions. But it heavily depends on the pathologist's judgment ability — very reliant on the physician's "eye for detail." In primary care hospitals with limited experience and equipment, it's like "a blind person fishing" — over 30% of CIN2+ (high-grade lesions) may be missed or misdiagnosed, leading to overtreatment or anxiety. So cytology results have problems of both "making a mountain out of a molehill" (unnecessary examinations) and "escapees" (missed diagnoses).
Simply put: Both existing methods, limited by their sensitivity and specificity, increase colposcopy referral rates and invasive cervical assessments, each with strengths but neither achieving both. Therefore, high sensitivity combined with high specificity is the gold standard.
02 CISCER® Methylation Testing (PAX1/JAM3): The "Dual-Insurance Scout" for Cervical Health
The CISCER® methylation test (PAX1/JAM3) is a "dual-gene scout" designed specifically for cervical cancer — more precise and sensitive than general methylation tests. It's like a "dual-lens camera" that, unlike traditional methods examining "surface phenomena" (virus or cell morphology), delves inside cells to simultaneously capture the "switch status" of two key genes (PAX1 and JAM3) — this is "methylation." Abnormal gene "switches" (methylation) are often early signals that cells are beginning to transform and progress toward cancer. Capturing "latent signals" at the gene level provides an extra "all-seeing eye" beyond conventional testing.
Why Is It a "Dual-Insurance Scout"? Three Key Strengths:
- "Dual Blades Combined" — Broader Coverage, Fewer Misses
PAX1 specializes in squamous cell carcinoma (accounting for over 70% of cervical cancers), capturing early gene "switch abnormalities" in squamous carcinoma. JAM3 covers both adenocarcinoma and squamous carcinoma, being more sensitive to less common types (such as adenocarcinoma) with broader coverage.
Example:
Single-gene testing is like a "monocular telescope" that may miss blind spots; dual-gene testing is like "binocular vision" — PAX1 and JAM3 working together provide a field of view with no blind spots, significantly reducing missed diagnosis risk!
- Higher Sensitivity, Earlier Warning — Staying Ahead of Invisible Lesions
CISCER® improves sensitivity by 20% compared to general methylation tests, capable of detecting earlier, more dangerous precancerous lesions (such as CIN3), even microscopically invisible abnormalities (high-grade lesions or focal cancer).
Research shows: CISCER®'s detection rate for HSIL (high-grade lesions) is 15% higher than conventional testing. Early detection, early intervention — naturally better treatment outcomes!
- Precise "Lesion Targeting" — Reducing Unnecessary Examinations
A positive CISCER® result can precisely identify high-risk areas, helping physicians determine whether biopsy or surgery is needed, avoiding unnecessary overtreatment — saving both money and worry.
03 Early Detection Enables Early Treatment — Methylation Testing Enables "Prevention Before It Happens"
The success of CISCER® methylation reagents marks China's transition from "following" to "leading" in the field of cervical cancer molecular diagnostics. Its technological accessibility, clinical precision, and social value not only build a health defense for hundreds of millions of women but also set a benchmark for domestically developed innovative medical devices.
Looking ahead, with technological iteration and policy support, CISCER® is expected to lead global cervical cancer screening into the "methylation era," truly achieving the ultimate goal of "early detection, early treatment" and safeguarding the health and happiness of more women! Don't miss screening because of "fear of hassle" or "embarrassment" — use the "sharp weapon" of modern technology to proactively put "dual insurance" on your health!
Beijing Origin CISPOLY Biotechnology Co., Ltd. is a technology-driven enterprise committed to health innovation. As a pioneer in the field of early gynecologic oncology diagnosis, CISPOLY has developed early-detection products for cervical cancer, endometrial cancer, and ovarian cancer using proprietary technologies and patent-protected biomarkers, filling a critical gap in the field.
As women pay increasing attention to their own health, the women's health market holds great potential. Beyond the early screening and diagnosis product pipeline for gynecologic oncology, CISPOLY will continue to build additional women's health product lines, establishing itself as a technology-innovation-leading enterprise in the women's health market.